



SCREENING FOR LATENT TUBERCULOSIS INFECTION (LTBI) PRIOR TO USE OF BIOLOGICAL AGENTS IN AUSTRALIA*

* DISCLAIMER

This guideline is to be read in conjunction with RECOMMENDATIONS FOR THE USE OF BIOLOGICAL AGENTS FOR THE TREATMENT OF RHEUMATIC DISEASES, <http://www.rheumatology.org.au>

INTRODUCTION

The utilisation of biological agents in Australia which includes the tumour necrosis factor (TNF) inhibitors have both changed and challenge the management of rheumatic diseases particularly rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

Rheumatologists remain the largest group of Australian medical practitioners prescribing these therapies since their subsidisation on the Pharmaceutical Benefits Scheme (PBS) from July 2003 onwards. We are in the unique position of providing a user perspective aided by and subject to continuing change with updated rheumatology literature.

TNF INHIBITORS AND TUBERCULOSIS RISK

The cytokine TNF not only has a major role causing inflammation in the pathogenesis of some rheumatic diseases, psoriasis and inflammatory bowel disease, but also plays an integral role in defence against infection including mycobacterium causing tuberculosis infection (TBI).

An increased susceptibility to active tuberculosis infection (TBI) or reactivation of latent TBI (LTBI) has been reported for all TNF inhibitors. Those currently available in Australia are etanercept (Enbrel) a human TNF soluble receptor fusion protein, adalimumab (Humira) a human recombinant monoclonal antibody and infliximab (Remicade) a chimeric human / mouse monoclonal antibody. There have been more reported cases of reactivation of LTBI for infliximab and adalimumab versus etanercept use which may be in part due to differences in monoclonal antibody versus soluble receptor TNF inhibitor actions. However, as no head to head comparisons among TNF inhibitors have been carried out to date, there is no definitive data on relative incidence of reactivation of latent to active TBI.

The risk of reactivation of TB also depends on the underlying rate of latent infection or risk of previous TB infection in the population. There are also high risk groups for TB infection including injecting drug addiction, HIV infection, a history of working or living in TB high risk settings such as prison, and finally people on immunosuppressive medications particularly corticosteroids as occurs in many of our patients with rheumatic diseases.

In the USA, the background rate of TB in American patients with RA who had not received a TNF inhibitor was 6.2 cases per 100,000. The Australian background rate is slightly less. LTBI is by definition asymptomatic and only 10% of people with LTBI normally go on to active TBI. Treatment of LTBI cases before TNF inhibitor commencement decreases the incidence of active TBI development by more than 80%.

This was well demonstrated with early infliximab use for RA overseas with its risk of the development of active TB five fold. The crude world rate of TBI in RA patients receiving infliximab was 47.6 / 100,000 (2001) which subsequently fell with LTBI screening programs to 24.4 / 100,000.

The following guideline has been developed to reduce the risk of active TBI in Australian rheumatic disease patients receiving TNF inhibitors. There will be initial discussion on the screening modalities available for LTBI, and why Australian guidelines a slightly differ from those of overseas.

SCREENING MODALITIES FOR LTBI

Prospective screening with 3 of 4 modalities for all patients starting TNF inhibitors should be considered.

1. A case history TB risk factor assessment with physical examination **AND**
2. Chest radiograph (CXR) **AND**
3. Two-step tuberculin skin test (TST) **OR**
Interferon gamma release assay (IGRA) such as QuantiFERON-TB Gold (QFT-G) blood test (Cellestis, Melbourne, Vic).

The British Thoracic Society recommends:

- asking about TB risk factors
 - performing a chest radiograph
- BUT NOT A Mantoux (TST) because of its reduced sensitivity in a setting of immunosuppression including corticosteroid use.

Treatment of LTBI is considered for select patients with TB risk factors even if the chest radiograph is normal (in addition to those with chest radiograph changes or past history of TBI).

The Centres of Disease Control (USA) recommends:

- Asking about TB risk factors
 - Mantoux TST testing of cases with TB risk factors
- OR alternatively an Interferon Gamma Release Assay (IGRA) for selected populations including immunosuppressed cases.
BUT a chest radiograph is performed **ONLY** if treatment of LTBI is planned, to exclude active TBI.

Treatment of LTBI may be considered in patients with a negative Mantoux TST test if there are convincing epidemiological risk factors.

An algorithm for LTBI screening for Australian rheumatic disease patients commencing TNF inhibitors recommends:

1. A case history TB risk factor assessment with physical examination **AND**
2. Chest radiograph (CXR) **AND**
3. Two-step tuberculin skin test (TST) **OR**
Interferon gamma release assay (IGRA) such as QuantiFERON-TB Gold (QFT-G) blood test (Cellestis, Melbourne, Vic).

The scored case history risk assessment involving ten questions is easy to perform and remains the most important modality.

Patients are then recommended to have either a two step TST or IGRA depending on availability, convenience, and particularly consider for those on immunomodulators or with BCG vaccination.

Finally all patients have a chest x-ray to assess evidence of past or current possible TB infection (e.g. calcified nodular lesions, apical fibrosis, pleural scarring).

Any positive high risk modality response as per the algorithm should be referred to the local TB expert be it an infectious disease or respiratory physician for consideration of LTBI treatment. If multiple positive moderate risk modality response referral for LTBI treatment needs to be considered on a case by case basis which includes the not inconsiderable hepatotoxicity risk with isoniazid use for LTBI. "Blind" treatment of LTBI is not recommended.

The majority of cases with reactivation of LTBI to active TBI occur within 12 weeks of onset of TNF inhibitor use and over 50% have extra pulmonary TB site infection. If a patient becomes unwell with fever and weight loss on TNF inhibitor treatment, the possibility of TBI should be considered even if initial LTBI screening tests were negative.


Patients with LTBI are usually recommended to commence isoniazid (5mg/kg/d, maximum <300mg/d) with pyridoxine (25mg/d) for 6-9 months or rifampicin (10mg/kg/d maximum, <600mg/d) for four months. There is general consensus that TNF inhibitor therapy can be commenced concurrently 1-2 months after.

Patients with active TB should cease their TNF inhibitor, minimise use of other immunomodulators and be referred to the local TB expert be it an infectious diseases or respiratory physician.

With respect to other biological therapies for rheumatic diseases there has been no evidence of increased susceptibility or incidence of TB. However most of these patients have been screened or have previously received TNF inhibitors and thus pre-screened for possible LTBI.

The rheumatologist should always be vigilant for the occurrence of TB in any of his or her patients on biological agents.

Figure 1. ALGORITHM for LTBI screening for patients commencing TNF inhibitors. Each modality assesses whether patients are at low (L), moderate (M) or high (H) risk. Any high risk modality response should be referred to the local TB expert for consideration LTBI treatment. Consider LTBI therapy if multiple moderate risk modalities. Adapted from Perera LC, Tymms KE, Dorai Raj AK et al. IMJ 2006: 36(Suppl 2):A29



^Each question stratifies a patient into a risk category. Patient is classed as the highest category they have obtained. If patient answered yes to more than one moderate risk category question, they are still classed as moderate risk

*high TB prevalence countries include India, Pakistan, Bangladesh, China, Phillipines, Indonesia, Ethiopia, Nigeria, South Africa, Congo

#The Interferon Gamma Release Assay (IGRA) test QuantiFERON-TB Gold has been suggested as an alternative to 2 step TST to eliminate TST false negatives for those with rheumatic diseases on immuno-modulators. Consider IGRA also for false positives from possible past BCG or atypical mycobacteria infection. Refer occasional persistent indeterminate IGRA result to local TB expert.

REFERENCES

1. Keane J, Bresnihan B
Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies.
Curr Opin Rheumatol.2008 Jul;20(4):443-9
2. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumour necrosis factor antagonists.
Arthritis Rheum 2005;52:1766-72
3. Sellam J, Handi H, Roy C et al
For the RATIO Study Group. Comparison of in vitro - specific blood test with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF.
Ann Rheum 2007;66:1610-5
4. Ponce dL, Acevedo-Vasquez E, Sanchez-Torres A et al
Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis.
Ann Rheum Dis 2005;64:1360-1
5. Centres for Disease Control and Prevention
Tuberculosis associated with blocking agents against tumour necrosis factor-alpha:California, 2002-2003.
MMWR 2004;53:683-6
6. British Thoracic Society Standards Of Care Committee
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment
Thorax 2005;60:800-805
7. Perera I.C. Tyvms KE. Dorai Rai AK et al
^Each question stratifies a patient into a risk category. Patient ng TNF is classed as the highest category they have obtained. If patient answered yes to more than one moderate risk category question, they are still classed as moderate risk
8. *high TB prevelance countries include India, Pakistan, Bangladesh, China, Phillipines, Indonesia, Ethiopia, Nigeria, South Africa, tecting Congo
#The Interferon Gamma Release Assav (IGRA) test QuantiFERON-TB Gold has been suggested as an alternative to 2
9. Matulis G, Jüni P, Villiger PM et al
Detection of latent tuberculosis in immunosuppressed patients with autoimmune disease: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay
Ann Rheum Dis 2008;67:84-90
10. Furst DE, Keystone EC, Kirkham B et al
Updated consensus statement on biological agents for the treatment of rheumatic disease, 2008
Ann Rheum Dis 2008;67(Suppl III):ii2-ii25